InMIND
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- NCT04680052 ↗
- Active, not recruiting
- Incyte Corporation
- Deep
We haven't built an HCP commentary report on InMIND (tafasitamab in relapsed/refractory follicular lymphoma or marginal zone lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on InMIND so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 52 | |
| Podcasts | 25 | |
| X threads | 23 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Follicular Lymphoma; Marginal Zone Lymphoma
- Interventions
- tafasitamab; rituximab; lenalidomide; placebo
- Arms
- Arm A : tafasitamab + rituximab + lenalidomide · Experimental
- Arm B : placebo+rituximab+lenalidomide · Placebo comparator
- Enrollment
- 654
- Primary outcomes
- FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First
- FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First
- Sponsor
- Incyte Corporation
- Start
- Apr 15, 2021
- Primary completion
- Feb 23, 2024
- Results posted
- Yes
- Registry record
- NCT04680052 · updated Sep 4, 2026
Publications
linked from the registry- Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M; inMIND Study team. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. Lancet. 2026 Jan 10;407(10524):133-146. doi: 10.1016/S0140-6736(25)01778-7. Epub 2025 Dec 5. PubMed 41360064